Regeneron Pharmaceuticals Inc. (REGN) Shares Sold by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado decreased its position in Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 2.9% during the second quarter, Holdings Channel reports. The fund owned 16,510 shares of the biopharmaceutical company’s stock after selling 500 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Regeneron Pharmaceuticals were worth $5,766,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Advisory Services Network LLC boosted its position in Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 326 shares during the period. Bessemer Group Inc. boosted its position in Regeneron Pharmaceuticals by 45.4% in the first quarter. Bessemer Group Inc. now owns 548 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 171 shares during the period. CIBC World Markets Inc. bought a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $202,000. Jacobs Levy Equity Management Inc. bought a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $207,000. Finally, QUANTRES ASSET MANAGEMENT Ltd bought a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $210,000. Hedge funds and other institutional investors own 68.32% of the company’s stock.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded up 1.31% during midday trading on Tuesday, hitting $371.53. The stock had a trading volume of 414,019 shares. The firm has a market cap of $38.87 billion, a price-to-earnings ratio of 57.96 and a beta of 1.31. The firm has a 50 day moving average of $395.85 and a 200 day moving average of $392.36. Regeneron Pharmaceuticals Inc. has a 52 week low of $329.09 and a 52 week high of $592.59.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.17. The company earned $1.21 billion during the quarter, compared to the consensus estimate of $1.24 billion. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The firm’s revenue for the quarter was up 21.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.89 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals Inc. will post $11.02 EPS for the current year.

REGN has been the subject of a number of research reports. Roth Capital reissued a “buy” rating and issued a $520.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 4th. Leerink Swann reissued a “buy” rating and issued a $530.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, September 21st. Goldman Sachs Group Inc. reiterated a “buy” rating and issued a $521.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 27th. Chardan Capital reiterated a “sell” rating and issued a $325.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, September 30th. Finally, Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 4th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $480.09.

In related news, Director Joseph L. Goldstein sold 2,125 shares of the company’s stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $425.00, for a total transaction of $903,125.00. Following the completion of the transaction, the director now owns 15,125 shares in the company, valued at $6,428,125. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 10.40% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN).

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Disney to Build Larger Hong Kong Kingdom
Disney to Build Larger Hong Kong Kingdom
DraftKings and FanDuel Finally Will Merge
DraftKings and FanDuel Finally Will Merge


 
© 2006-2016 Ticker Report. Google+.